GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » WIN-Partners Co Ltd (TSE:3183) » Definitions » Debt-to-EBITDA

WIN-Partners Co (TSE:3183) Debt-to-EBITDA : 0.00 (As of Dec. 2023)


View and export this data going back to 2013. Start your Free Trial

What is WIN-Partners Co Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

WIN-Partners Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was 円0 Mil. WIN-Partners Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was 円0 Mil. WIN-Partners Co's annualized EBITDA for the quarter that ended in Dec. 2023 was 円2,917 Mil. WIN-Partners Co's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was 0.00.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for WIN-Partners Co's Debt-to-EBITDA or its related term are showing as below:

During the past 13 years, the highest Debt-to-EBITDA Ratio of WIN-Partners Co was 1.47. The lowest was 0.00. And the median was 1.40.

TSE:3183's Debt-to-EBITDA is not ranked *
in the Medical Distribution industry.
Industry Median: 2.375
* Ranked among companies with meaningful Debt-to-EBITDA only.

WIN-Partners Co Debt-to-EBITDA Historical Data

The historical data trend for WIN-Partners Co's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

WIN-Partners Co Debt-to-EBITDA Chart

WIN-Partners Co Annual Data
Trend Mar12 Mar13 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

WIN-Partners Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of WIN-Partners Co's Debt-to-EBITDA

For the Medical Distribution subindustry, WIN-Partners Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


WIN-Partners Co's Debt-to-EBITDA Distribution in the Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, WIN-Partners Co's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where WIN-Partners Co's Debt-to-EBITDA falls into.



WIN-Partners Co Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

WIN-Partners Co's Debt-to-EBITDA for the fiscal year that ended in Mar. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0) / 3111.125
=0.00

WIN-Partners Co's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0) / 2916.832
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.


WIN-Partners Co  (TSE:3183) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


WIN-Partners Co Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of WIN-Partners Co's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


WIN-Partners Co (TSE:3183) Business Description

Traded in Other Exchanges
N/A
Address
2-2-1 Kyobashi, Chuoku, 21st Floor, Kyobashi Edogrand, Tokyo, JPN, 104-0031
WIN-Partners Co Ltd is engaged in the healthcare sector. The company provides medical devices to Japan's medical institutions. Its products offerings are Cardiovascular device, Insulin Pump, X-ray Angio System, Carotid Artery Stent, Stent Graft, among others.

WIN-Partners Co (TSE:3183) Headlines

No Headlines